AOD-9604 in Maglavit — Fat Loss Peptide Research Guide
AOD-9604 research guide for Maglavit. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.
For anyone in Maglavit searching for AOD-9604, the first thing to know is that this compound is available only through an online research supply market. The key implication for Maglavit researchers: sourcing AOD-9604 hinges on vendor quality evaluation, not geography — and the quality verification approach is identical for researchers everywhere. Vendors worth sourcing from openly share batch-matched Certificates of Analysis showing HPLC chromatograms, mass spec identity confirmation, endotoxin levels, and residual solvent results — all for the precise product run you are purchasing. What follows is a sourcing and quality evaluation guide built specifically around AOD-9604, covering everything a Maglavit researcher needs to source confidently.
How AOD-9604 Works — Mechanisms & Research
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: AOD-9604 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Maglavit comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
Where to Buy AOD-9604 — A Researcher's Guide
Vetting AOD-9604 vendors requires starting from the COA: request the batch-specific certificate before purchasing, not after. Endotoxin testing in the COA is essential for any injectable research use — endotoxins from bacterial cell wall components can trigger serious immune reactions even at minute levels. Community reputation in research forums is a useful additional signal to COA verification — vendors with consistently positive reports over 12+ months have built their reputation on real product performance. For Maglavit researchers making a first AOD-9604 purchase: apply these quality criteria before ordering, order conservatively at first, and check that batch numbers on your vial match the COA before use.
Order AOD-9604 — ships to Maglavit
COA-verified · International tracking · Research grade
Research compound status for AOD-9604 means the safety evidence is drawn from animal studies, in-vitro work, and limited human observations — rather than the comprehensive clinical trial data that characterises approved medications. Lyophilised AOD-9604 should be stored frozen (−20°C) immediately upon receipt; repeated freeze-thaw cycles of reconstituted material should be avoided by aliquoting into single-use portions. Verify the endotoxin level in your AOD-9604 batch COA before use in any in-vivo protocol — look for results expressed as EU/mg or EU/mL and compare against acceptable research limits for your application. PubMed are the primary literature resources for AOD-9604 research; favour indexed journal publications over preprints over unreviewed preprints or forum reports.
Frequently Asked Questions
What is AOD-9604?
AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.
How does AOD-9604 differ from growth hormone?
AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.
What is the clinical trial history of AOD-9604?
AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.
